搜索到 1000 条关于 어양야설추천 Ap131.top 후카다 에이미 레지티비썰 덕천댁스토리 soB 的文章
-
-
2021.08.02 2021 年 6 月最受欢迎的品牌案例
本期「TOP list ·月度案例评选」是基于 6 月在丁香园医院汇平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10排名医院
-
-
2020.06.30 2020 年 6 月最受欢迎的品牌案例
本期「TOP list ·月度案例评选」是基于 6 月在丁香园 医院汇 平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10
-
-
2015.11.14 丁香园力荐 最受医生欢迎的 20 本必备好书
「借花献佛」,和大家分享下推荐最多的 10 本 「案头必备」和 10 本 「床头必备」好书。一、案头必备TOP 1. 实用内科学推荐理由:中国医学界唯一一部畅销...出版一次,已出至第14版,可及时反映国内外进展,是内科领域各级学科医师的 「不二宝典」。TOP 2. 坎贝尔骨科手术学推荐理由:国际权威骨科经典著作,内含众多
-
-
2013.12.27 2013年5大重磅新药
2013年岁末已至,回首这一年,一批「重磅炸弹」级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top1 默克...晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2 糖尿病治疗的新突破强生和Evotec公司共同开发
-
-
2013.12.25 盘点2013年改变世界的5大重磅新药
2013年岁末已至,回首这一年,一批"重磅炸弹"级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top...积极的数据。制药巨头正准备将晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2:糖尿病治疗的新突破强生和Evotec公司
-
-
2019.09.02 最新重症胰腺炎诊疗指南:合格的「摸金校尉」治疗篇
抗微生物药物治疗的正确疗程如何?预防性使用抗生素指南内容1. 最近的证据表明,AP 患者预防性使用抗生素并没有显著降低病死率或并发症发生率。因此,不再推荐对所有 AP 患者常规预防性使用抗生素(1A)。虽然早期的试验表明无菌性坏死的患者使用抗生素可能会预防感染性并发症,但后续的设计更好的试验
-
-
2014.03.11 标准不一,又何谈学术伦理?
ligase),可以催化它的 15 个长链氨基酸受体肽(amino acid acceptor peptide, AP)受质中的赖氨酸(Lysine)生物素化(biotinylation)反应。所以,生物素化的 AP 即可和含萤光的共轭链酶亲和素(streptavidin)结合,如此便可观测到活神经细胞表面交互作用的萤光
-
-
2016.08.09 七夕节:话一话古代十大奇葩避孕方式
CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入
-
2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)
时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话:+65 650 82401
-
2012.09.19 2010 第五届国际基因组学大会(ICG-V)
, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster
-
-
2014.11.26 清醒麻醉下经皮内镜脓肿切除术可有效治疗胰腺脓肿
急性胰腺炎(acute pancreatitis,AP)可分为间质水肿型及坏死型,其中后者可引起诸多并发症,并存在一定的死亡率,与死亡率相关的因素包括脏器衰竭及胰腺脓肿(infected pancreatic necrosis,IPN)。 AP早期患者主要死于脏器衰竭,称之为重型胰腺炎或爆发性胰腺炎,晚期死亡的主要
-
2012.09.19 2012 中国医疗器械高峰论坛
trials and regulatory affairs A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
-
-
2017.08.23 高再荣教授专访:难治性甲状腺癌的治疗策略
,包括碘 131 全身扫描、颈部超声、CT 和磁共振等;三是分子标志物的检测。以上都是评价 RAI 治疗效果的重要手段。在评估过程中,必须贯穿一个很重要的理念,即动态评估。因为评价疗效不是一次决定终身,而是应该根据碘 131 治疗的时间和病情变化进行动态分层。丁香园:目前,国际上对于 RAI 抵抗的标准还存在争议,对此
-
-
2016.09.19 EMA 专家小组建议批准辉瑞乳腺癌药物Ibrance
幅上涨。Ibrance 在 2015 年 2 月获得美国食品和药物管理局批准,在最近的一个季度中,为辉瑞公司 131 亿美元的季度销售额贡献了约 5 亿美元
-
-
2016.06.30 王肖原主任中医师
王肖原,主任中医师。杭州市基层名中医,儿科疾病专家。浙江省中医药学会儿科分会常务委员及青年委员会副主任委员、萧山中医药学会理事。萧山跨世纪科技人才培养人选、杭州市新世纪「131」 优秀中青年人才第三层次培养人选、第三批全国优秀中医临床人才。一直在中医儿科临床工作,曾先后师从省级名老中医宣桂琪、国家级名老中医王霞芳
-
-
2014.03.17 中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较
随着甲状腺癌发病率的上升,国内开始重视甲状腺结节及分化型甲状腺癌的治疗,并发布了最新的相关指南,该指南与美国国立综合癌症网络(NCCN)、美国甲状腺学会(ATA)指南相比,在甲状腺结节术前评估、手术方式、术后131I 治疗及促甲状腺激素(TSH)抑制治疗方面均更加贴近我国国情,尤其是增加了良性甲状腺结节的治疗建议
-
-
2011.10.20 多次复发的甲亢病例一例
手术治疗又颇为忌惮,是否须I131治疗或中医针灸治疗(据说传统医学在治疗甲亢方面有独特的疗效);3:如继续口服药物,方案如何调整?请各位老师、同仁赐教。曾春霞:患者心率、血压、血常规是否正常?如果反复发作,无碘131治疗禁忌症,本人还是会建议碘131治疗,不过一定要跟病人说明会引起甲减的副作用,并且有40